These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32065426)

  • 1. The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease.
    Singleton AB; Gasser T
    Mov Disord; 2020 Apr; 35(4):551-554. PubMed ID: 32065426
    [No Abstract]   [Full Text] [Related]  

  • 2. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors.
    Cogo S; Greggio E; Lewis PA
    Expert Opin Ther Targets; 2017 Aug; 21(8):751-753. PubMed ID: 28609155
    [No Abstract]   [Full Text] [Related]  

  • 4. LRRK2 pathobiology in Parkinson's disease - virtual inclusion.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2016 Oct; 139 Suppl 1():75-76. PubMed ID: 26899799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).
    Beylina A; Langston RG; Rosen D; Reed X; Cookson MR
    Stem Cell Res; 2021 May; 53():102354. PubMed ID: 34087985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 and the new era of Parkinson's disease research.
    The Lancet Neurology
    Lancet Neurol; 2016 Nov; 15(12):1195. PubMed ID: 27751534
    [No Abstract]   [Full Text] [Related]  

  • 8. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting
    Leśniak RK; Nichols RJ; Smith M; Montine TJ
    Future Med Chem; 2022 Aug; 14(16):1167-1170. PubMed ID: 35730403
    [No Abstract]   [Full Text] [Related]  

  • 10. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 links genetic and sporadic Parkinson's disease.
    Kluss JH; Mamais A; Cookson MR
    Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Grisanti S; Ferri L; Cavallieri F; Fioravanti V; Vincenzi C; Toschi G; Grisendi I; Sabadini R; Paul JJ; Bauer P; Zedde M; Valzania F
    Mov Disord; 2022 May; 37(5):1117-1118. PubMed ID: 35587629
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
    Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
    J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Kojovic M; Kassavetis P; Pareés I; Georgiev D; Rocchi L; Balint B; Foltynie T; Rothwell J; Bhatia K
    Mov Disord; 2017 Sep; 32(9):1333-1335. PubMed ID: 28686318
    [No Abstract]   [Full Text] [Related]  

  • 17. LRRK2 R1441C mutation causing Parkinson's Disease in an Egyptian family.
    Ali S; Wszolek ZK
    Neurol Neurochir Pol; 2022; 56(2):191-192. PubMed ID: 35029295
    [No Abstract]   [Full Text] [Related]  

  • 18. Leucine rich repeat kinase 2: a paradigm for pleiotropy.
    Lewis PA
    J Physiol; 2019 Jul; 597(14):3511-3521. PubMed ID: 31124140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 mutations in Parkinson's disease patients from Central Europe: A case control study.
    Skorvanek M; Rizig M; Athanasiou-Fragkouli A; Necpal J; Straka I; Tamas G; Kurca E; Mosejova A; Han V; Lorincova T; Ostrozovicova M; Liesenerova S; Levicka P; Fajcikova L; Minar M; Valkovic P; Mákos O; Kelemen A; Grofik M; Cibulka M; Jama F; Houlden H;
    Parkinsonism Relat Disord; 2021 Feb; 83():110-112. PubMed ID: 33561776
    [No Abstract]   [Full Text] [Related]  

  • 20. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.